Delivery Order SPE2DB22D1200-SPE2DB25FN4BL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,143.87 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with DLA. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,267.84 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on September 3, 2025, with completion by September 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,584.34 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This firm fixed-price, non-competitive delivery order is set to be completed by August 19, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $11,831.93 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pens on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a single delivery order fulfillment for pharmaceutical supplies to support federal medical procurement needs. The contract is being performed at AmerisourceBergen's Corporate Office...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens valued at $9,721.62. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $8,408.08. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $41,202.03 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-competitive, firm fixed-price delivery order is being fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical...
- The Defense Logistics Agency awarded a $5,630.51 delivery order to AmerisourceBergen Drug Corp on August 10, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This firm fixed price contract, with an ultimate completion date of August 11, 2025, represents a small-value pharmaceutical procurement supporting federal medical supply needs. The award was made on a competitive basis without any set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $6,863.22 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 17, 2025, with an ultimate completion date of July 18, 2025. This competitively awarded, firm fixed-price delivery order represents a single-line pharmaceutical supply transaction with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 14, 2025. The contract is classified as firm fixed price with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the company's capability to meet...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN4BLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,894.04 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pens. This competitively awarded, firm fixed-price contract requires completion by August 28, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The delivery order was issued with no set-aside designation, reflecting open competition in accordance with federal procurement standards. This delivery order represents a small transaction within AmerisourceBergen Drug Corp's broader relationship with the DLA, operating as a child order under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing comprehensive medical supplies and medications to support military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical devices across multiple therapeutic areas to government healthcare customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 8/27/25 |